학술논문

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Document Type
Article
Source
Investigational New Drugs; Aug2013, Vol. 31 Issue 4, p833-844, 12p
Subject
ANIMAL experimentation
ANTINEOPLASTIC agents
BIOAVAILABILITY
CELL lines
DRUG design
CLINICAL drug trials
ENZYMES
GENETICS
MICE
GENETIC mutation
PHOSPHOTRANSFERASES
CHEMICAL inhibitors
PHARMACODYNAMICS
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)